Active surveillance for favorable-risk prostate cancer: Is there a greater psychological impact than previously thought? A systematic, mixed studies literature review

Psycho-Oncology

Volumn 26, Issue 10, 2017, Pages 1411-1421

  Ruane McAteer, Eimear ^a   Porter, Sam ^b   O'Sullivan, Joe M ^a,c   Santin, Olinda ^a   Prue, Gillian ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BOURNEMOUTH UNIVERSITY   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

active surveillance; anxiety; cancer; depression; oncology; prostatic neoplasms; uncertainty

Indexed keywords

ANXIETY; CANCER EPIDEMIOLOGY; CANCER RISK; CLINICAL PRACTICE; DEPRESSION; DISEASE ASSOCIATION; GENERAL PRACTITIONER; HEALTH IMPACT ASSESSMENT; HUMAN; PRACTICE GUIDELINE; PREVALENCE; PROSTATE CANCER; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL WELL-BEING; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; REVIEW; SAMPLE SIZE; STUDY DESIGN; SUPPORT GROUP; SYSTEMATIC REVIEW; HEALTH SURVEY; MALE; PROCEDURES; PROSTATE TUMOR; PSYCHOLOGY; QUALITY OF LIFE; UNCERTAINTY;

ANXIETY; DEPRESSION; HUMANS; MALE; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; UNCERTAINTY;

EID: 85008256310     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.4311     Document Type: Review

References (36)

1. Lawrentschuk N, Klotz L. Active surveillance for favorable-risk prostate cancer: a short review. Korean J Urol. 2010;51(10):665–670. doi: 10.4111/kju.2010.51.10.665
2. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol. 2005;23(32):8165–8169. doi: 10.1200/JCO.2005.03.3134
3. National Institute for Health and Clinical Excellence. Prostate Cancer: Diagnosis and Treatment (CG175). 2014. http://www.nice.org.uk/guidance/CG175. Accessed September 16, 2016.
4. Bergman J, Litwin MS. Quality of life in men undergoing active surveillance for localized prostate cancer. J Natl Cancer Inst Monogr. 2012 Sep;2012(45):242. doi: 10.1093/jncimonographs/lgs026
5. Bellardita L, Valdagni R, van den Bergh R, et al. How does active surveillance for prostate cancer affect quality of life? A systematic review. Eur Urol. 2014;1–9. doi: 10.1016/j.eururo.2014.10.028
6. Carter G, Clover K, Britton B, et al. Wellbeing during active surveillance for localised prostate cancer: a systematic review of psychological morbidity and quality of life. Cancer Treat Rev. 2015;41:46–60. doi: 10.1016/j.ctrv.2014.11.001
7. Curry L, Nembhard IM, Bradley EH. Qualitative and mixed methods provide unique contributions to outcomes research. Circulation. 2009;119(10):1442–1452. doi: 10.1161/CIRCULATIONAHA.107.742775
8. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535
9. Litwin MS, Talcott JA. Measuring quality of life in prostate cancer: progress and challenges. In: Lipscomb J, Gotay CC, Snyder C, eds. Outcomes Assessment in Cancer. Cambridge, UK: University Press; 2005:126–159.
10. Pluye P, Robert E, Cargo M, et al. Proposal: A Mixed Methods Appraisal Tool for Systematic Mixed Studies Reviews. Montréal: McGill University; 2011.
11. Pace R, Pluye P, Bartlett G, et al. Testing the reliability and efficiency of the pilot Mixed Methods Appraisal Tool (MMAT) for systematic mixed studies review. Int J Nurs Stud. 2012;49(1):47–53. doi: 10.1016/j.ijnurstu.2011.07.002
12. Anderson J, Burney S, Brooker JE, et al. Anxiety in the management of localised prostate cancer by active surveillance. BJU Int. 2014;114: 55–61. doi: 10.1111/bju.12765Suppl
13. Bellardita L, Rancati T, Alvisi MF, et al. Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol. 2013;64(1):30–36. doi: 10.1016/j.eururo.2013.01.009
14. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int. 2007;100(3):540–543. doi: 10.1111/j.1464-410X.2007.07009.x
15. Couper JW, Love AW, Dunai JV, et al. The psychological aftermath of prostate cancer treatment choices: a comparison of depression, anxiety and quality of life outcomes over the 12 months following diagnosis. Med J Aust. 2009;190(7):S86–S89.
16. Goh AC, Kowalkowski MA, Bailey DE Jr, Kazer MW, Knight SJ, Latini DM. Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance. BJU Int. 2012;110(2B):E50-E56.
17. Hegarty JM, Wallace M, Comber H. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland. Am J Mens Health. 2008;2(2):133–142. doi: 10.1177/1557988307300467
18. Latini DM, Hart SL, Knight SJ, Cowan JE, Ross PL, DuChane J. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007;178(3):826–831. doi: 10.1016/j.juro.2007.05.039
19. Parker PA, Davis JW, Latini DM, et al. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2015. doi: 10.1111/bju.13099
20. Pearce SM, Wang CHE, Victorson DE, et al. A longitudinal study of predictors of sexual dysfunction in men on active surveillance for prostate cancer. Sex Med. 2015;3(3):156–164. doi: 10.1002/sm2.78
21. Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013;112(2):E67–E75. doi: 10.1111/bju.12209
22. Seiler D, Randazzo M, Leupold U, et al. Protocol-based active surveillance for low-risk prostate cancer: anxiety levels in both men and their partners. Urology. 2012;80(3):564–569. doi: 10.1016/j.urology.2012.04.053
23. Selli C, Bjartell A, Burgos J, et al. Burden of illness in prostate cancer patients with a low-to-moderate risk of progression: a one-year, pan-European observational study. Prostate Cancer. 2014;201:1–8.
24. van den Bergh RCN, Essink-Bot M-L, Roobol MJ, et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009;115(17):3868–3878. doi: 10.1002/cncr.24446
25. van den Bergh RCN, Essink-Bot M-L, Roobol MJ, Schroder FH, Bangma CH, Steyerberg EW. Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol. 2010;183(5):1786–1791. doi: 10.1016/j.juro.2009.12.099
26. van den Bergh RCN, Korfage IJ, Roobol MJ, et al. Sexual function with localized prostate cancer: active surveillance vs radical therapy. BJU Int. 2012;110(7):1032–1039. doi: 10.1111/j.1464-410X.2011.10846.x
27. Venderbos LDF, van den Bergh RCN, Roobol MJ, et al. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psychooncology. 2014. doi: 10.1002/pon.3657
28. Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum. 2003;30(2):303–309. doi: 10.1188/03.ONF.303-309
29. Watts S, Leydon G, Eyles C, et al. A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance. BMJ Open. 2015;5(5):e006674. doi: 10.1136/bmjopen-2014-006674
30. Wilcox CB, Gilbourd D, Louie-Johnsun M. Anxiety and health-related quality of life (HRQL) in patients undergoing active surveillance of prostate cancer in an Australian centre. BJU Int 2014;113(Suppl 2):64–68. doi:10.1111/bju.12557
31. Yanez B, Bustillo NE, Antoni MH, et al. The importance of perceived stress management skills for patients with prostate cancer in active surveillance. J Behav Med. 2014. doi: 10.1007/s10865-014-9594-1
32. Hedestig O, Sandman P-O, Widmark A. Living with untreated localized prostate cancer. Cancer Nurs. 2003;26(1):55–60. doi: 10.1097/00002820-200302000-00008
33. Kazer MW. Conversion from active surveillance to active treatment for prostate cancer: a qualitative analysis. J Nurs Educ Pract. 2012;2(2):80–88. doi: 10.5430/jnep.v2n2p80
34. Oliffe JL, Davison BJ, Pickles T, Mroz L. The self-management of uncertainty among men undertaking active surveillance for low-risk prostate cancer. Qual Health Res. 2009;19(4):432–443. doi: 10.1177/1049732309332692
35. Sharpley CF, Christie DR, Bitsika V. Variability in anxiety and depression over time following diagnosis in patients with prostate cancer. J Psychosoc Oncol. 2010 Nov 2;28(6):644–665.
36. Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013;djt151